Hoth Therapeutics, Inc. announced it has received Human Research Ethics Committee (HREC) clearence to commence the first cohort of the Phase 1b clinical trial of BioLexa Lotion. The lotion will be used for the treatment of mild to modrate atopic dermatitis in Australia and is expected to treat the first subject in early 2021, with top-line data from the first cohort of the trial expected in the first quarter of 2021. Pending the succesful completion of the Phase 1b trial, the company intends to conduct a Phase 2 trial with adult and adolescent patients to continue clinical investigation of the lotion's efficacy. Yourway is well positioned to support clinical trials in dermatology.